Ferroptosis: A New Therapeutic Target for Neurological Diseases

Berndt C, Alborzinia H, Amen VS, Ayton S, Barayeu U, Bartelt A, et al. Ferroptosis in health and disease. Redox Biol. 2024;75:103211. Yan HF, Zou T, Tuo QZ, Xu S, Li H, Belaidi AA, et al. Ferroptosis: mechanisms and links with diseases. Signal Transduct Target Ther. 2021;6:49. Yan HF, Tuo QZ, Yin QZ, Lei P. The pathological role of ferroptosis in ischemia/reperfusion-related injury. Zool Res. 2020;41:220–30. Lei P, Walker T, Ayton S. Neuroferroptosis in health and diseases. Nat Rev Neurosci. 2025;26:497–511. Jiang X, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol. 2021;22:266–82. Stockwell BR, Friedmann Angeli JP, Bayir H, Bush AI, Conrad M, Dixon SJ, et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 2017;171:273–85. Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060–72. Thi Nghiem TH, Kusuma F, Park J, Joe Y, Chung HT, Han J. Brief guide to detecting ferroptosis. Molecules Cell. 2025;48:100276. Stockwell BR. Ferroptosis turns 10: Emerging mechanisms, physiological functions, and therapeutic applications. Cell. 2022;185:2401–21. Yoon JH, Seo Y, Jo YS, Lee S, Cho E, Cazenave-Gassiot A, et al. Brain lipidomics: from functional landscape to clinical significance. Sci Adv. 2022;8:eadc9317. Halcrow PW, Lynch ML, Geiger JD, Ohm JE. Role of endolysosome function in iron metabolism and brain carcinogenesis. Semin cancer Biol. 2021;76:74–85. Raichle ME, Gusnard DA. Appraising the brain’s energy budget. Proc Natl Acad Sci USA. 2002;99:10237–9. Ward RJ, Zucca FA, Duyn JH, Crichton RR, Zecca L. The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurol. 2014;13:1045–60. Cheng Z, Li Y. What is responsible for the initiating chemistry of iron-mediated lipid peroxidation: an update. Chem Rev. 2007;107:748–66. Cenini G, Lloret A, Cascella R. Oxidative stress in neurodegenerative diseases: from a mitochondrial point of view. Oxid Med Cell Longev. 2019;2019:2105607. Guo J, Huang X, Dou L, Yan M, Shen T, Tang W, et al. Aging and aging-related diseases: from molecular mechanisms to interventions and treatments. Signal Transduct Target Ther. 2022;7:391. Halliwell B. Understanding mechanisms of antioxidant action in health and disease. Nat Rev Mol Cell Biol. 2024;25:13–33. Ramsey CP, Glass CA, Montgomery MB, Lindl KA, Ritson GP, Chia LA, et al. Expression of Nrf2 in neurodegenerative diseases. J neuropathology Exp Neurol. 2007;66:75–85. Sakuragi T, Nagata S. Regulation of phospholipid distribution in the lipid bilayer by flippases and scramblases. Nat Rev Mol Cell Biol. 2023;24:576–96. Qiu B, Zandkarimi F, Bezjian CT, Reznik E, Soni RK, Gu W, et al. Phospholipids with two polyunsaturated fatty acyl tails promote ferroptosis. Cell. 2024;187:1177–1190.e1118. Mariamenatu AH, Abdu EM. Overconsumption of omega-6 polyunsaturated fatty acids (PUFAs) versus deficiency of omega-3 PUFAs in modern-day diets: the disturbing factor for their “balanced antagonistic metabolic functions” in the human body. J lipids. 2021;2021:8848161. Bazinet RP, Layé S. Polyunsaturated fatty acids and their metabolites in brain function and disease. Nat Rev Neurosci. 2014;15:771–85. Tuo QZ, Lei P. Ferroptosis in ischemic stroke: animal models and mechanisms. Zool Res. 2024;45:1235–48. Tuo QZ, Liu Y, Xiang Z, Yan HF, Zou T, Shu Y, et al. Thrombin induces ACSL4-dependent ferroptosis during cerebral ischemia/reperfusion. Signal Transduct Target Ther. 2022;7:59. Luoqian J, Yang W, Ding X, Tuo QZ, Xiang Z, Zheng Z, et al. Ferroptosis promotes T-cell activation-induced neurodegeneration in multiple sclerosis. Cell Mol immunology. 2022;19:913–24. Du B, Deng Z, Chen K, Yang Z, Wei J, Zhou L, et al. Iron promotes both ferroptosis and necroptosis in the early stage of reperfusion in ischemic stroke. Genes Dis. 2024;11:101262. Russo GL. Dietary n-6 and n-3 polyunsaturated fatty acids: from biochemistry to clinical implications in cardiovascular prevention. Biochemical pharmacology. 2009;77:937–46. Saini RK, Keum YS. Omega-3 and omega-6 polyunsaturated fatty acids: dietary sources, metabolism, and significance - a review. Life Sci. 2018;203:255–67. Norris PC, Dennis EA. Omega-3 fatty acids cause dramatic changes in TLR4 and purinergic eicosanoid signaling. Proc Natl Acad Sci USA. 2012;109:8517–22. Alves F, Lane D, Nguyen TPM, Bush AI, Ayton S. In defence of ferroptosis. Signal Transduct Target Ther. 2025;10:2. Tuo QZ, Zhang ST, Lei P. Mechanisms of neuronal cell death in ischemic stroke and their therapeutic implications. Med Res Rev. 2022;42:259–305. Dixon SJ, Olzmann JA. The cell biology of ferroptosis. Nat Rev Mol Cell Biol. 2024;25:424–42. Dixon SJ, Pratt DA. Ferroptosis: a flexible constellation of related biochemical mechanisms. Mol Cell. 2023;83:1030–42. Yang WS, Stockwell BR. Ferroptosis: death by lipid peroxidation. Trends Cell Biol. 2016;26:165–76. Kagan VE, Mao G, Qu F, Angeli JP, Doll S, Croix CS, et al. Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nat Chem Biol. 2017;13:81–90. Shi P, Song C, Qi H, Ren J, Ren P, Wu J, et al. Up-regulation of IRF3 is required for docosahexaenoic acid suppressing ferroptosis of cardiac microvascular endothelial cells in cardiac hypertrophy rat. J nutritional Biochem. 2022;104:108972. Schaefer EJ, Bongard V, Beiser AS, Lamon-Fava S, Robins SJ, Au R, et al. Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and alzheimer disease: the framingham heart study. Arch Neurol. 2006;63:1545–50. Heude B, Ducimetière P, Berr C. Cognitive decline and fatty acid composition of erythrocyte membranes-The EVA Study. Am J Clin Nutr. 2003;77:803–8. Quinn JF, Raman R, Thomas RG, Yurko-Mauro K, Nelson EB, Van Dyck C, et al. Docosahexaenoic acid supplementation and cognitive decline in alzheimer disease: a randomized trial. Jama. 2010;304:1903–11. Perluigi M, Sultana R, Cenini G, Di Domenico F, Memo M, Pierce WM, et al. Redox proteomics identification of 4-hydroxynonenal-modified brain proteins in Alzheimer’s disease: Role of lipid peroxidation in alzheimer’s disease pathogenesis. Proteom Clin Appl. 2009;3:682–93. Ansari MA, Scheff SW. Oxidative stress in the progression of alzheimer disease in the frontal cortex. J neuropathology Exp Neurol. 2010;69:155–67. Benseny-Cases N, Klementieva O, Cotte M, Ferrer I, Cladera J. Microspectroscopy (μFTIR) reveals co-localization of lipid oxidation and amyloid plaques in human Alzheimer disease brains. Anal Chem. 2014;86:12047–54. Sayre LM, Zelasko DA, Harris PL, Perry G, Salomon RG, Smith MA. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in alzheimer’s disease. J Neurochem. 1997;68:2092–7. Yoo MH, Gu X, Xu XM, Kim JY, Carlson BA, Patterson AD, et al. Delineating the role of glutathione peroxidase 4 in protecting cells against lipid hydroperoxide damage and in alzheimer’s disease. Antioxid redox Signal. 2010;12:819–27. Keller JN, Schmitt FA, Scheff SW, Ding Q, Chen Q, Butterfield DA, et al. Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology. 2005;64:1152–6. Butterfield DA, Reed T, Perluigi M, De Marco C, Coccia R, Cini C, et al. Elevated protein-bound levels of the lipid peroxidation product, 4-hydroxy-2-nonenal, in brain from persons with mild cognitive impairment. Neurosci Lett. 2006;397:170–3. Pedersen WA, Fu W, Keller JN, Markesbery WR, Appel S, Smith RG, et al. Protein modification by the lipid peroxidation product 4-hydroxynonenal in the spinal cords of amyotrophic lateral sclerosis patients. Ann Neurol. 1998;44:819–24. Tang F, Zhou LY, Li P, Jiao LL, Chen K, Guo YJ, et al. Inhibition of ACSL4 Alleviates Parkinsonism Phenotypes by Reduction of Lipid Reactive Oxygen Species. Neurotherapeutics. 2023;20:1154–66. Fu Y, He Y, Phan K, Bhatia S, Pickford R, Wu P, et al. Increased unsaturated lipids underlie lipid peroxidation in synucleinopathy brain. Acta neuropathologica Commun. 2022;10:165. Dexter D, Carter C, Agid F, Agid Y, Lees AJ, Jenner P, et al. Lipid peroxidation as cause of nigral cell death in Parkinson’s disease. Lancet. 1986;2:639–40. Dexter DT, Carter CJ, Wells FR, Javoy-Agid F, Agid Y, Lees A, et al. Basal lipid peroxidation in substantia nigra is increased in parkinson’s disease. J Neurochem. 1989;52:381–9. Mazhari Dorooee D, Ravez S, Vertommen D, Renault N, Papadopoulos N, Marteau R, et al. LIBX-A401: A Novel Selective Inhibitor of Acyl-CoA Synthetase Long Chain Family Member 4 (ACSL4) and Its Binding Mode. Angew Chem. 2025;64:e202500518. Charnelle E, Gobert A, Marteau R, Pautric M, Renault N, Jonneaux A, et al. Discovery of potent Acyl-CoA synthetase long-chain family member 4 (ACSL4) inhibitors with antiferroptotic properties. J medicinal Chem. 2025;68:15766–84. Angelova PR, Choi ML, Berezhnov AV, Horrocks MH, Hughes CD, De S, et al. Alpha synuclein aggregation drives ferroptosis: an interplay of iron, calcium and lipid peroxidation. Cell death Differ. 2020;27:2781–96. Angelova PR, Horrocks MH, Klenerman D, Gandhi S, Abramov AY, Shchepinov MS. Lipid peroxidation is essential for α-synuclein-induced cell death. J neurochemistry. 2015;133:582–9. Sun WY, Tyurin VA, Mikulska-Ruminska K, Shrivastava IH, Anthonymuthu TS, Zhai YJ, et al. Phospholipase iPLA(2)β averts ferroptosis by eliminating a redox lipid death signal. Nat Chem Biol. 2021;17:465–76. Kinghorn KJ, Castillo-Quan JI, Bartolome F, Angelova PR, Li L, Pope S, et al. Loss of PLA2G6 leads to elevated mitochondrial lipid peroxidation and mitochondrial dysfunction. Brain. 2015;138:1801–16. Jung JE, Karatas H, Liu Y, Yalcin A, Montaner J, Lo EH, et al. STAT-dependent upregulation of 12/15-lipoxygenase contributes to neuronal injury after stroke. J Cereb blood flow Metab. 2015;35:2043–51. Levi S, Ripamonti M, Moro AS, Cozzi A. Iron imbalance in neurodegeneration. Mol psychiatry. 2024;29:1139–52. Wu D, Chen Q, Chen X, Han F, Chen Z, Wang Y. The blood-brain barrier: structure, regulation, and drug delivery. Signal Transduct Target Ther. 2023;8:217. McCarthy RC, Kosman DJ. Iron transport across the blood-brain barrier: development, neurovascular regulation and cerebral amyloid angiopathy. Cell Mol life Sci. 2015;72:709–27. McCarthy RC, Kosman DJ. Mechanisms and regulation of iron trafficking across the capillary endothelial cells of the blood-brain barrier. Front Mol Neurosci. 2015;8:31. Connor JR, Menzies SL, St Martin SM, Mufson EJ. A histochemical study of iron, transferrin, and ferritin in alzheimer’s diseased brains. J Neurosci Res. 1992;31:75–83. Jefferies WA, Brandon MR, Hunt SV, Williams AF, Gatter KC, Mason DY. Transferrin receptor on endothelium of brain capillaries. Nature. 1984;312:162–3. Lambe T, Simpson RJ, Dawson S, Bouriez-Jones T, Crockford TL, Lepherd M, et al. Identification of a Steap3 endosomal targeting motif essential for normal iron metabolism. Blood. 2009;113:1805–8. McCarthy RC, Kosman DJ. Ferroportin and exocytoplasmic ferroxidase activity are required for brain microvascular endothelial cell iron efflux. J Biol Chem. 2013;288:17932–40. Moos T. Brain iron homeostasis. Dan Med Bull. 2002;49:279–301. Jeong SY, David S. Glycosylphosphatidylinositol-anchored ceruloplasmin is required for iron efflux from cells in the central nervous system. J Biol Chem. 2003;278:27144–8. Rouault TA. Iron metabolism in the CNS: implications for neurodegenerative diseases. Nat Rev Neurosci. 2013;14:551–64. Frey AG, Nandal A, Park JH, Smith PM, Yabe T, Ryu MS, et al. Iron chaperones PCBP1 and PCBP2 mediate the metallation of the dinuclear iron enzyme deoxyhypusine hydroxylase. Proc Natl Acad Sci USA. 2014;111:8031–6. Mancias JD, Wang X, Gygi SP, Harper JW, Kimmelman AC. Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagy. Nature. 2014;509:105–9. Kakhlon O, Cabantchik ZI. The labile iron pool: characterization, measurement, and participation in cellular processes(1). Free Radic Biol Med. 2002;33:1037–46. Kruszewski M. Labile iron pool: the main determinant of cellular response to oxidative stress. Mutat Res. 2003;531:81–92. Ru Q, Li Y, Chen L, Wu Y, Min J, Wang F. Iron homeostasis and ferroptosis in human diseases: mechanisms and therapeutic prospects. Signal Transduct Target Ther. 2024;9:271. Li Y, Du Y, Zhou Y, Chen Q, Luo Z, Ren Y, et al. Iron and copper: critical executioners of ferroptosis, cuproptosis and other forms of cell death. Cell Commun Signal. 2023;21:327. Tuo QZ, Lei P, Jackman KA, Li XL, Xiong H, Li XL, et al. Tau-mediated iron export prevents ferroptotic damage after ischemic stroke. Mol psychiatry. 2017;22:1520–30. Kerins MJ, Ooi A. The roles of NRF2 in modulating cellular iron homeostasis. Antioxid redox Signal. 2018;29:1756–73. Suh JH, Shenvi SV, Dixon BM, Liu H, Jaiswal AK, Liu RM, et al. Decline in transcriptional activity of Nrf2 causes age-related loss of glutathione synthesis, which is reversible with lipoic acid. Proc Natl Acad Sci USA. 2004;101:3381–6. Schmidlin CJ, Dodson MB, Madhavan L, Zhang DD. Redox regulation by NRF2 in aging and disease. Free Radic Biol Med. 2019;134:702–7. Tao Y, Wang Y, Rogers JT, Wang F. Perturbed iron distribution in alzheimer’s disease serum, cerebrospinal fluid, and selected brain regions: a systematic review and meta-analysis. J Alzheimer’s Dis. 2014;42:679–90. Ayton S, Portbury S, Kalinowski P, Agarwal P, Diouf I, Schneider JA, et al. Regional brain iron associated with deterioration in alzheimer’s disease: a large cohort study and theoretical significance. Alzheimer’s & dementia : the journal of the Alzheimer’s. Association. 2021;17:1244–56. Ashraf A, Jeandriens J, Parkes HG, So PW. Iron dyshomeostasis, lipid peroxidation and perturbed expression of cystine/glutamate antiporter in alzheimer’s disease: evidence of ferroptosis. Redox Biol. 2020;32:101494. Bulk M, Abdelmoula WM, Geut H, Wiarda W, Ronen I, Dijkstra J, et al. Quantitative MRI and laser ablation-inductively coupled plasma-mass spectrometry imaging of iron in the frontal cortex of healthy controls and alzheimer’s disease patients. NeuroImage. 2020;215:116808. Damulina A, Pirpamer L, Soellradl M, Sackl M, Tinauer C, Hofer E, et al. Cross-sectional and longitudinal assessment of brain iron level in alzheimer disease using 3-T MRI. Radiology. 2020;296:619–26. Bartzokis G, Sultzer D, Cummings J, Holt LE, Hance DB, Henderson VW, et al. In vivo evaluation of brain iron in alzheimer disease using magnetic resonance imaging. Arch Gen psychiatry. 2000;57:47–53. De Reuck JL, Deramecourt V, Auger F, Durieux N, Cordonnier C, Devos D, et al. Iron deposits in post-mortem brains of patients with neurodegenerative and cerebrovascular diseases: a semi-quantitative 7.0 T magnetic resonance imaging study. Eur J Neurol. 2014;21:1026–31. Du L, Zhao Z, Cui A, Zhu Y, Zhang L, Liu J, et al. Increased iron deposition on brain quantitative susceptibility mapping correlates with decreased cognitive function in alzheimer’s disease. ACS Chem Neurosci. 2018;9:1849–57. Bao WD, Pang P, Zhou XT, Hu F, Xiong W, Chen K, et al. Loss of ferroportin induces memory impairment by promoting ferroptosis in alzheimer’s disease. Cell death Differ. 2021;28:1548–62. Ayton S, Wang Y, Diouf I, Schneider JA, Brockman J, Morris MC, et al. Brain iron is associated with accelerated cognitive decline in people with alzheimer pathology. Mol psychiatry. 2020;25:2932–41. Dávalos A, Castillo J, Marrugat J, Fernandez-Real JM, Armengou A, Cacabelos P, et al. Body iron stores and early neurologic deterioration in acute cerebral infarction. Neurology. 2000;54:1568–74. Millan M, Sobrino T, Castellanos M, Nombela F, Arenillas JF, Riva E, et al. Increased body iron stores are associated with poor outcome after thrombolytic treatment in acute stroke. Stroke. 2007;38:90–95. Guo Y, Wang Y, Ni Y, Bo B, He J, Zhu Y et al. Iron overload mediates the differential cell fate of astrocytes from neurons and its regulatory mechanisms in ischemic stroke. Advanced science 2025: e07384. Dietrich RB, Bradley WG Jr. Iron accumulation in the basal ganglia following severe ischemic-anoxic insults in children. Radiology. 1988;168:203–6. Ayton S, Lei P. Nigral iron elevation is an invariable feature of Parkinson’s disease and is a sufficient cause of neurodegeneration. BioMed Res Int. 2014;2014:581256. Acosta-Cabronero J, Machts J, Schreiber S, Abdulla S, Kollewe K, Petri S, et al. Quantitative susceptibility MRI to detect brain iron in amyotrophic lateral sclerosis. Radiology. 2018;289:195–203. Kasarskis EJ, Tandon L, Lovell MA, Ehmann WD. Aluminum, calcium, and iron in the spinal cord of patients with sporadic amyotrophic lateral sclerosis using laser microprobe mass spectroscopy: a preliminary study. J neurological Sci. 1995;130:203–8. Rosas HD, Chen YI, Doros G, Salat DH, Chen NK, Kwong KK, et al. Alterations in brain transition metals in Huntington disease: an evolving and intricate story. Arch Neurol. 2012;69:887–93. Agrawal S, Fox J, Thyagarajan B, Fox JH. Brain mitochondrial iron accumulates in huntington’s disease, mediates mitochondrial dysfunction, and can be removed pharmacologically. Free Radic Biol Med. 2018;120:317–29. Kotamraju S, Chitambar CR, Kalivendi SV, Joseph J, Kalyanaraman B. Transferrin receptor-dependent iron uptake is responsible for doxorubicin-mediated apoptosis in endothelial cells: role of oxidant-induced iron signaling in apoptosis. J Biol Chem. 2002;277:17179–87. Zhao Y, Yang M, Liang X. The role of mitochondria in iron overload-induced damage. J Transl Med. 2024;22:1057. Wang P, Zheng SY, Jiang RL, Wu HD, Li YA, Lu JL, et al. Necroptosis signaling and mitochondrial dysfunction cross-talking facilitate cell death mediated by chelerythrine in glioma. Free Radic Biol Med. 2023;202:76–96. Tian Q, Qin B, Gu Y, Zhou L, Chen S, Zhang S, et al. ROS-Mediated necroptosis is involved in iron overload-induced osteoblastic cell death. Oxid Med Cell Longev. 2020;2020:1295382. Zhu L, Hu J, Wu X, Zhang J, Xu X, Huang X, et al. Programmed enhancement of endogenous iron-mediated lysosomal membrane permeabilization for tumor ferroptosis/pyroptosis dual-induction. Nat Commun. 2025;16:3017. Lee S, Hwang N, Seok BG, Lee S, Lee SJ, Chung SW. Autophagy mediates an amplification loop during ferroptosis. Cell death Dis. 2023;14:464. Bousejra-ElGarah F, Bijani C, Coppel Y, Faller P, Hureau C. Iron(II) binding to amyloid-β, the alzheimer’s peptide. Inorg Chem. 2011;50:9024–30. Khan MA. Targeting iron responsive elements (IREs) of APP mRNA into novel therapeutics to control the translation of amyloid-β precursor protein in alzheimer’s disease. Pharmaceuticals. 2024;17:1669. Tian S, Wang B, Ding Y, Zhang Y, Yu P, Chang YZ, et al. The role of iron transporters and regulators in alzheimer’s disease and Parkinson’s disease: Pathophysiological insights and therapeutic prospects. Biomed Pharmacother. 2024;179:117419. Huang X, Atwood CS, Hartshorn MA, Multhaup G, Goldstein LE, Scarpa RC, et al. The a beta peptide of alzheimer’s disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry. 1999;38:7609–16. Lane DJR, Ayton S, Bush AI. Iron and Alzheimer’s Disease: An Update on Emerging Mechanisms. J Alzheimer’s Dis. 2018;64:S379–s395. Matsuo ES, Shin RW, Billingsley ML, Van deVoorde A, O’Connor M, Trojanowski JQ, et al. Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as alzheimer’s disease paired helical filament tau. Neuron. 1994;13:989–1002. Compta Y, Parkkinen L, O’Sullivan SS, Vandrovcova J, Holton JL, Collins C, et al. Lewy- and Alzheimer-type pathologies in Parkinson’s disease dementia: which is more important? Brain. 2011;134:1493–505. Lei P, Ayton S, Finkelstein DI, Spoerri L, Ciccotosto GD, Wright DK, et al. Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Nat Med. 2012;18:291–5. Long H, Zhu W, Wei L, Zhao J. Iron homeostasis imbalance and ferroptosis in brain diseases. MedComm. 2023;4:e298. Deas E, Cremades N, Angelova PR, Ludtmann MH, Yao Z, Chen S, et al. Alpha-Synuclein oligomers interact with metal ions to induce oxidative stress and neuronal death in parkinson’s disease. Antioxid redox Signal. 2016;24:376–91. Park JH, Burgess JD, Faroqi AH, DeMeo NN, Fiesel FC, Springer W, et al. Alpha-synuclein-induced mitochondrial dysfunction is mediated via a sirtuin 3-dependent pathway. Mol neurodegeneration. 2020;15:5. Chen Y, Luo X, Yin Y, Thomas ER, Liu K, Wang W, et al. The interplay of iron, oxidative stress, and α-synuclein in Parkinson’s disease progression. Mol Med. 2025;31:154. Boag MK, Roberts A, Uversky VN, Ma L, Richardson DR, Pountney DL. Ferritinophagy and α-synuclein: pharmacological targeting of autophagy to restore iron regulation in parkinson’s disease. Int J Mol Sci. 2022;23:2378. Baksi S, Tripathi AK, Singh N. Alpha-synuclein modulates retinal iron homeostasis by facilitating the uptake of transferrin-bound iron: implications for visual manifestations of Parkinson’s disease. Free Radic Biol Med. 2016;97:292–306. Duce JA, Wong BX, Durham H, Devedjian JC, Smith DP, Devos D. Post translational changes to α-synuclein control iron and dopamine trafficking; a concept for neuron vulnerability in Parkinson’s disease. Mol neurodegeneration. 2017;12:45. Niu L, Ye C, Sun Y, Peng T, Yang S, Wang W, et al. Mutant huntingtin induces iron overload via up-regulating IRP1 in Huntington’s disease. Cell Biosci. 2018;8:41. Anzovino A, Lane DJ, Huang ML, Richardson DR. Fixing frataxin: ‘ironing out’ the metabolic defect in Friedreich’s ataxia. Br J pharmacology. 2014;171:2174–90. Read AD, Bentley RE, Archer SL, Dunham-Snary KJ. Mitochondrial iron-sulfur clusters: structure, function, and an emerging role in vascular biology. Redox Biol. 2021;47:102164. Hayyan M, Hashim MA, AlNashef IM. Superoxide ion: generation and chemical implications. Chem Rev. 2016;116:3029–85. Ledo A, Fernandes E, Salvador A, Laranjinha J, Barbosa RM. In vivo hydrogen peroxide diffusivity in brain tissue supports volume signaling activity. Redox Biol. 2022;50:102250. Hamanaka RB, Chandel NS. Mitochondrial reactive oxygen species regulate cellular signaling and dictate biological outcomes. Trends biochemical Sci. 2010;35:505–13. Sies H, Belousov VV, Chandel NS, Davies MJ, Jones DP, Mann GE, et al. Defining roles of specific reactive oxygen species (ROS) in cell biology and physiology. Nat Rev Mol Cell Biol. 2022;23:499–515. Massaad CA, Klann E. Reactive oxygen species in the regulation of synaptic plasticity and memory. Antioxid redox Signal. 2011;14:2013–54. Dixon SJ, Stockwell BR. The role of iron and reactive oxygen species in cell death. Nat Chem Biol. 2014;10:9–17. Wang Y, Branicky R, Noë A, Hekimi S. Superoxide dismutases: dual roles in controlling ROS damage and regulating ROS signaling. J Cell Biol. 2018;217:1915–28. Brigelius-Flohé R, Maiorino M. Glutathione peroxidases. Biochimica et biophysica acta. 2013;1830:3289–303. Pei J, Pan X, Wei G, Hua Y. Research progress of glutathione peroxidase family (GPX) in redoxidation. Front pharmacology. 2023;14:1147414. Tuo QZ, Masaldan S, Southon A, Mawal C, Ayton S, Bush AI, et al. Characterization of selenium compounds for anti-ferroptotic activity in neuronal cells and after cerebral ischemia-reperfusion injury. Neurotherapeutics. 2021;18:2682–91. Lubos E, Loscalzo J, Handy DE. Glutathione peroxidase-1 in health and disease: from molecular mechanisms to therapeutic opportunities. Antioxid redox Signal. 2011;15:1957–97. Manful CF, Fordjour E, Subramaniam D, Sey AA, Abbey L, Thomas R. Antioxidants and reactive oxygen species: shaping human health and disease outcomes. Int J Mol Sci. 2025;26:7520. Chabory E, Damon C, Lenoir A, Kauselmann G, Kern H, Zevnik B, et al. Epididymis seleno-independent glutathione peroxidase 5 maintains sperm DNA integrity in mice. J Clin investigation. 2009;119:2074–85. Taylor A, Robson A, Houghton BC, Jepson CA, Ford WC, Frayne J. Epididymal specific, selenium-independent GPX5 protects cells from oxidative stress-induced lipid peroxidation and DNA mutation. Hum Reprod. 2013;28:2332–42. Nguyen VD, Saaranen MJ, Karala AR, Lappi AK, Wang L, Raykhel IB, et al. Two endoplasmic reticulum PDI peroxidases increase the efficiency of the use of peroxide during disulfide bond formation. J Mol Biol. 2011;406:503–15. Yoboue ED, Rimessi A, Anelli T, Pinton P, Sitia R. Regulation of calcium fluxes by GPX8, a type-II transmembrane peroxidase enriched at the mitochondria-associated endoplasmic reticulum membrane. Antioxid redox Signal. 2017;27:583–95. Hu Q, You H, Li K, Lai L, Song C. GPx4 is bound to peroxidized membranes by a hydrophobic anchor. J Mol Biol. 2025;437:169122. Borchert A, Kalms J, Roth SR, Rademacher M, Schmidt A, Holzhutter HG, et al. Crystal structure and functional characterization of selenocysteine-containing glutathione peroxidase 4 suggests an alternative mechanism of peroxide reduction. Biochim Biophys Acta Mol Cell Biol Lipids. 2018;1863:1095–107. Gong M, Hay S, Marshall KR, Munro AW, Scrutton NS. DNA binding suppresses human AIF-M2 activity and provides a connection between redox chemistry, reactive oxygen species, and apoptosis. J Biol Chem. 2007;282:30331–40. Bersuker K, Hendricks JM, Li Z, Magtanong L, Ford B, Tang PH, et al. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature. 2019;575:688–92. Doll S, Freitas FP, Shah R, Aldrovandi M, da Silva MC, Ingold I, et al. FSP1 is a glutathione-independent ferroptosis suppressor. Nature. 2019;575:693–8. Mao C, Liu X, Zhang Y, Lei G, Yan Y, Lee H, et al. DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer. Nature. 2021;593:586–90. Mishima E, Nakamura T, Zheng J, Zhang W, Mourão ASD, Sennhenn P, et al. DHODH inhibitors sensitize to ferroptosis by FSP1 inhibition. Nature. 2023;619:E9–e18. Wang F, Min J. DHODH tangoing with GPX4 on the ferroptotic stage. Signal Transduct Target Ther. 2021;6:244. Traber MG. Mechanisms for the prevention of vitamin E excess. J lipid Res. 2013;54:2295–306. Seiler A, Schneider M, Förster H, Roth S, Wirth EK, Culmsee C, et al. Glutathione peroxidase 4 senses and translates oxidative stress into 12/15-lipoxygenase dependent- and AIF-mediated cell death. Cell Metab. 2008;8:237–48. Mishima E, Ito J, Wu Z, Nakamura T, Wahida A, Doll S, et al. A non-canonical vitamin K cycle is a potent ferroptosis suppressor. Nature. 2022;608:778–83. Tschuck J, Padmanabhan Nair V, Galhoz A, Zaratiegui C, Tai HM, Ciceri G, et al. Suppression of ferroptosis by vitamin a or radical-trapping antioxidants is essential for neuronal development. Nat Commun. 2024;15:7611. Kraft VAN, Bezjian CT, Pfeiffer S, Ringelstetter L, Müller C, Zandkarimi F, et al. GTP cyclohydrolase 1/tetrahydrobiopterin counteract ferroptosis through lipid remodeling. ACS Cent Sci. 2020;6:41–53. Soula M, Weber RA, Zilka O, Alwaseem H, La K, Yen F, et al. Metabolic determinants of cancer cell sensitivity to canonical ferroptosis inducers. Nat Chem Biol. 2020;16:1351–60. Stover PJ, Field MS. Trafficking of intracellular folates. Adv Nutr. 2011;2:325–31. Cario H, Smith DE, Blom H, Blau N, Bode H, Holzmann K, et al. Dihydrofolate reductase deficiency due to a homozygous DHFR mutation causes megaloblastic anemia and cerebral folate deficiency leading to severe neurologic disease. Am J Hum Genet. 2011;88:226–31. Su LJ, Zhang JH, Gomez H, Murugan R, Hong X, Xu D, et al. Reactive oxygen species-induced lipid peroxidation in apoptosis, autophagy, and ferroptosis. Oxid Med Cell Longev. 2019;2019:5080843. Sambra V, Echeverria F, Valenzuela A, Chouinard-Watkins R, Valenzuela R. Docosahexaenoic and arachidonic acids as neuroprotective nutrients throughout the life cycle. Nutrients. 2021;13:986. Innis SM. Dietary (n-3) fatty acids and brain development. J Nutr. 2007;137:855–9. Savaskan NE, Borchert A, Bräuer AU, Kuhn H. Role for glutathione peroxidase-4 in brain development and neuronal apoptosis: specific induction of enzyme expression in reactive astrocytes following brain injury. Free Radic Biol Med. 2007;43:191–201. Barnes-Vélez JA, Aksoy Yasar FB, Hu J. Myelin lipid metabolism and its role in myelination and myelin maintenance. Innovation. 2023;4:100360. Fan B, Liu D, Qin J, Shi Z, Hu Z, Gao X, et al. Ferroptosis suppressor protein 1 regulated oligodendrocytes ferroptosis rescued by idebenone in spinal cord injury. Free Radic Biol Med. 2025;227:129–42. Kapralov AA, Yang Q, Dar HH, Tyurina YY, Anthonymuthu TS, Kim R, et al. Redox lipid reprogramming commands susceptibility of macrophages and microglia to ferroptotic death. Nat Chem Biol. 2020;16:278–90. Jiao L, Li X, Luo Y, Wei J, Ding X, Xiong H, et al. Iron metabolism mediates microglia susceptibility in ferroptosis. Front Cell Neurosci. 2022;16:995084. Ambani LM, Van Woert MH, Murphy S. Brain peroxidase and catalase in Parkinson disease. Arch Neurol. 1975;32:114–8. Choi IY, Lee P, Statland J, McVey A, Dimachkie M, Brooks W, et al. Reduction in cerebral antioxidant, glutathione (GSH), in patients with ALS: a preliminary study (P6.105). Neurology. 2015;84:P6.105. Alves F, Lane D, Wahida A, Jakaria M, Kalinowski P, Southon A, et al. Aberrant mitochondrial metabolism in alzheimer’s disease links energy stress with ferroptosis. Adv Sci. 2025;12:e04175. Majerníková N, Marmolejo-Garza A, Salinas CS, Luu MDA, Zhang Y, Trombetta-Lima M, et al. The link between amyloid β and ferroptosis pathway in Alzheimer’s disease progression. Cell death Dis. 2024;15:782. Bellinger FP, Bellinger MT, Seale LA, Takemoto AS, Raman AV, Miki T, et al. Glutathione peroxidase 4 is associated with neuromelanin in substantia nigra and dystrophic axons in putamen of Parkinson’s brain. Mol neurodegeneration. 2011;6:8. Wang T, Tomas D, Perera ND, Cuic B, Luikinga S, Viden A, et al. Ferroptosis mediates selective motor neuron death in amyotrophic lateral sclerosis. Cell death Differ. 2022;29:1187–98. Hu CL, Nydes M, Shanley KL, Morales Pantoja IE, Howard TA, Bizzozero OA. Reduced expression of the ferroptosis inhibitor glutathione peroxidase-4 in multiple sclerosis and experimental autoimmune encephalomyelitis. J neurochemistry. 2019;148:426–39. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59–62. Tu LF, Zhang TZ, Zhou YF, Zhou QQ, Gong HB, Liang L, et al. GPX4 deficiency-dependent phospholipid peroxidation drives motor deficits of ALS. J Adv Res. 2023;43:205–18. Crapper McLachlan DR, Dalton AJ, Kruck TP, Bell MY, Smith WL, Kalow W, et al. Intramuscular desferrioxamine in patients with Alzheimer’s disease. Lancet. 1991;337:1304–8. Ayton S, Barton D, Brew B, Brodtmann A, Clarnette R, Desmond P, et al. Deferiprone in alzheimer disease: a randomized clinical trial. JAMA Neurol. 2025;82:11–18. Devos D, Labreuche J, Rascol O, Corvol JC, Duhamel A, Guyon Delannoy P, et al. Trial of deferiprone in Parkinson’s disease. N Engl J Med. 2022;387:2045–55. Devos D, Rascol O, Meissner WG, Foubert-Samier A, Lewis S, Tranchant C, et al. Therapeutic modalities of deferiprone in Parkinson’s disease: SKY and EMBARK studies. J Parkinson’s Dis. 2025;15:72–86. Selim M, Foster LD, Moy CS, Xi G, Hill MD, Morgenstern LB, et al. Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurol. 2019;18:428–38. Day BJ. Catalase and glutathione peroxidase mimics. Biochemical pharmacology. 2009;77:285–96. Sies H. Ebselen, a selenoorganic compound as glutathione peroxidase mimic. Free Radic Biol Med. 1993;14:313–23. Sies H. Ebselen: a glutathione peroxidase mimic. Methods enzymology. 1994;234:476–82. Yamaguchi T, Sano K, Takakura K, Saito I, Shinohara Y, Asano T, et al. Ebselen in acute ischemic stroke: a placebo-controlled, double-blind clinical trial. Ebselen Study Group Stroke. 1998;29:12–17. Ogawa A, Yoshimoto T, Kikuchi H, Sano K, Saito I, Yamaguchi T, et al. Ebselen in acute middle cerebral artery occlusion: a placebo-controlled, double-blind clinical trial. Cerebrovasc Dis. 1999;9:112–8. Saito I, Asano T, Sano K, Takakura K, Abe H, Yoshimoto T, et al. Neuroprotective effect of an antioxidant, ebselen, in patients with delayed neurological deficits after aneurysmal subarachnoid hemorrhage. Neurosurgery. 1998;42:269–77. Li X, Shi Q, Xu H, Xiong Y, Wang C, Le L, et al. Ebselen interferes with Alzheimer’s disease by regulating mitochondrial function. Antioxidants. 2022;11:1350. Ursini F, Maiorino M. Lipid peroxidation and ferroptosis: The role of GSH and GPx4. Free Radic Biol Med. 2020;152:175–85. Pedre B, Barayeu U, Ezeriņa D, Dick TP. The mechanism of action of N-acetylcysteine (NAC): The emerging role of H(2)S and sulfane sulfur species. Pharmacology therapeutics. 2021;228:107916. Raftos JE, Whillier S, Chapman BE, Kuchel PW. Kinetics of uptake and deacetylation of N-acetylcysteine by human erythrocytes. Int J Biochem Cell Biol. 2007;39:1698–706. Rushworth GF, Megson IL. Existing and potential therapeutic uses for N-acetylcysteine: the need for conversion to intracellular glutathione for antioxidant benefits. Pharmacology therapeutics. 2014;141:150–9. Sabetghadam M, Mazdeh M, Abolfathi P, Mohammadi Y, Mehrpooya M. Evidence for a beneficial effect of oral N-acetylcysteine on functional outcomes and inflammatory biomarkers in patients with acute ischemic stroke. Neuropsychiatric Dis Treat. 2020;16:1265–78. Hoffer ME, Balaban C, Slade MD, Tsao JW, Hoffer B. Amelioration of acute sequelae of blast induced mild traumatic brain injury by N-acetyl cysteine: a double-blind, placebo controlled study. PLoS one. 2013;8:e54163. Adair JC, Knoefel JE, Morgan N. Controlled trial of N-acetylcysteine for patients with probable Alzheimer’s disease. Neurology. 2001;57:1515–7. Katz M, Won SJ, Park Y, Orr A, Jones DP, Swanson RA, et al. Cerebrospinal fluid concentrations of N-acetylcysteine after oral administration in Parkinson’s disease. Parkinsonism Relat Disord. 2015;21:500–3. Coles LD, Tuite PJ, Öz G, Mishra UR, Kartha RV, Sullivan KM, et al. Repeated-Dose oral N-Acetylcysteine in Parkinson’s disease: pharmacokinetics and effect on brain glutathione and oxidative stress. J Clin pharmacology. 2018;58:158–67. Monti DA, Zabrecky G, Kremens D, Liang TW, Wintering NA, Bazzan AJ, et al. N-Acetyl cysteine is associated with dopaminergic improvement in Parkinson’s Disease. Clin pharmacology therapeutics. 2019;106:884–90. Lotan A, Luza S, Opazo CM, Ayton S, Lane DJR, Mancuso S, et al. Perturbed iron biology in the prefrontal cortex of people with schizophrenia. Mol psychiatry. 2023;28:2058–70. Ravanfar P, Syeda WT, Jayaram M, Rushmore RJ, Moffat B, Lin AP, et al. In Vivo 7-Tesla MRI investigation of brain iron and its metabolic correlates in chronic schizophrenia. Schizophrenia. 2022;8:86. Stroup TS, Olfson M, Huang C, Wall MM, Goldberg T, Devanand DP, et al. Age-specific prevalence and incidence of dementia diagnoses among older us adults with schizophrenia. JAMA psychiatry. 2021;78:632–41. Van Rheenen TE, Cropley V, Zalesky A, Bousman C, Wells R, Bruggemann J, et al. Widespread volumetric reductions in schizophrenia and schizoaffective patients displaying compromised cognitive abilities. Schizophrenia Bull. 2018;44:560–74. Kumar J, Liddle EB, Fernandes CC, Palaniyappan L, Hall EL, Robson SE, et al. Glutathione and glutamate in schizophrenia: a 7T MRS study. Mol psychiatry. 2020;25:873–82. Berk M, Copolov D, Dean O, Lu K, Jeavons S, Schapkaitz I, et al. N-acetyl cysteine as a glutathione precursor for schizophrenia-a double-blind, randomized, placebo-controlled trial. Biol psychiatry. 2008;64:361–8. Clark RSB, Empey PE, Kochanek PM, Bell MJ. N-Acetylcysteine and Probenecid Adjuvant Therapy for Traumatic Brain Injury. Neurotherapeutics. 2023;20:1529–37. Rothstein JD. Edaravone: a new drug approved for ALS. Cell. 2017;171:725. Watanabe K, Tanaka M, Yuki S, Hirai M, Yamamoto Y. How is edaravone effective against acute ischemic stroke and amyotrophic lateral sclerosis? J Clin Biochem Nutr. 2018;62:20–38. Abe S, Kirima K, Tsuchiya K, Okamoto M, Hasegawa T, Houchi H, et al. The reaction rate of edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one (MCI-186)) with hydroxyl radical. Chem Pharm Bull. 2004;52:186–91. Yamashita T, Abe K. Update on antioxidant therapy with edaravone: expanding applications in neurodegenerative diseases. Int J Mol Sci. 2024;25:2945. Tabrizchi R Edaravone Mitsubishi-Tokyo. Current opinion in investigational drugs (London, England : 2000)2000; 1:347-54. Forman HJ, Zhang H. Targeting oxidative stress in disease: promise and limitations of antioxidant therapy. Nat Rev Drug discovery. 2021;20:689–709. Michaličková D, Kübra Öztürk H, Hroudová J, Ľupták M, Kučera T, Hrnčíř T, et al. Edaravone attenuates disease severity of experimental auto-immune encephalomyelitis and increases gene expression of Nrf2 and HO-1. Physiological Res. 2022;71:147–57. Zhang Y, Zou Z, Liu S, Chen F, Li M, Zou H, et al. Edaravone-loaded poly(amino acid) nanogel inhibits ferroptosis for neuroprotection in cerebral ischemia injury. Asian J Pharm Sci. 2024;19:100886. Kobayashi S, Fukuma S, Ikenoue T, Fukuhara S, Kobayashi S. Effect of edaravone on neurological symptoms in real-world patients with acute ischemic stroke. Stroke. 2019;50:1805–11. Witzel S, Maier A, Steinbach R, Grosskreutz J, Koch JC, Sarikidi A, et al. Safety and effectiveness of long-term intravenous administration of edaravone for treatment of patients with amyotrophic lateral sclerosis. JAMA Neurol. 2022;79:121–30. Guo J, Tuo QZ, Lei P. Iron, ferroptosis, and ischemic stroke. J Neurochem. 2023;165:487–520. Xu J, Wang A, Meng X, Yalkun G, Xu A, Gao Z, et al. Edaravone dexborneol versus edaravone alone for the treatment of acute ischemic stroke: a phase iii, randomized, double-blind, comparative trial. Stroke. 2021;52:772–80. Xu J, Wang Y, Wang A, Gao Z, Gao X, Chen H, et al. Safety and efficacy of edaravone dexborneol versus edaravone for patients with acute ischaemic stroke: a phase ii, multicentre, randomised, double-blind, multiple-dose, active-controlled clinical trial. Stroke Vasc Neurol. 2019;4:109–14. Chen HS, Zhao ZA, Shen XY, Qiu SQ, Cui Y, Qiu J, et al. Edaravone dexborneol for ischemic stroke with sufficient recanalization after thrombectomy: a randomized phase II trial. Nat Commun. 2025;16:2393. Boyd R. Selenium stories. Nat Chem. 2011;3:570. Ingold I, Berndt C, Schmitt S, Doll S, Poschmann G, Buday K, et al. Selenium utilization by GPX4 is required to prevent hydroperoxide-induced ferroptosis. Cell. 2018;172:409–22.e421. Zhang F, Li X, Wei Y. Selenium and selenoproteins in health. Biomolecules. 2023;13:799. Ramezani M, Simani L, Abedi S, Pakdaman H. Is selenium supplementation beneficial in acute ischemic stroke? neurologist. 2021;27:51–55. Sharifi-Razavi A, Karimi N, Jafarpour H. Evaluation of selenium supplementation in acute ischemic stroke outcome: an outcome assessor blind, randomized, placebo-controlled, feasibility study. Neurol India. 2022;70:87–93. Kryscio RJ, Abner EL, Caban-Holt A, Lovell M, Goodman P, Darke AK, et al. Association of antioxidant supplement use and dementia in the prevention of alzheimer’s disease by vitamin e and selenium trial (PREADViSE). JAMA Neurol. 2017;74:567–73. Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol. 2013;12:357–67. Schomburg L, Schweizer U. Hierarchical regulation of selenoprotein expression and sex-specific effects of selenium. Biochimica et biophysica acta. 2009;1790:1453–62. Cardoso BR, Hare DJ, Bush AI, Roberts BR. Glutathione peroxidase 4: a new player in neurodegeneration? Mol psychiatry. 2017;22:328–35. Solovyev ND. Importance of selenium and selenoprotein for brain function: from antioxidant protection to neuronal signalling. J Inorg Biochem. 2015;153:1–12. Atkinson J, Harroun T, Wassall SR, Stillwell W, Katsaras J. The location and behavior of alpha-tocopherol in membranes. Mol Nutr food Res. 2010;54:641–51. Leppälä JM, Virtamo J, Fogelholm R, Huttunen JK, Albanes D, Taylor PR, et al. Controlled trial of alpha-tocopherol and beta-carotene supplements on stroke incidence and mortality in male smokers. Arteriosclerosis, thrombosis, Vasc Biol. 2000;20:230–5. Gopalan Y, Shuaib IL, Magosso E, Ansari MA, Abu Bakar MR, Wong JW, et al. Clinical investigation of the protective effects of palm vitamin E tocotrienols on brain white matter. Stroke. 2014;45:1422–8. Dysken MW, Sano M, Asthana S, Vertrees JE, Pallaki M, Llorente M, et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. Jama. 2014;311:33–44. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. Alzheimer’s Dis Cooperative Study N Engl J Med. 1997;336:1216–22. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005;352:2379–88. Vatassery GT, Bauer T, Dysken M. High doses of vitamin E in the treatment of disorders of the central nervous system in the aged. Am J Clin Nutr. 1999;70:793–801. Lock M, Loblaw A. Vitamin E might increase risk of death. Can family physician Med de famille canadien. 2005;51:829–31. Zandi PP, Anthony JC, Khachaturian AS, Stone SV, Gustafson D, Tschanz JT, et al. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch Neurol. 2004;61:82–88. Naidu KA. Vitamin C in human health and disease is still a mystery? an overview. Nutr J. 2003;2:7. Agus DB, Gambhir SS, Pardridge WM, Spielholz C, Baselga J, Vera JC, et al. Vitamin C crosses the blood-brain barrier in the oxidized form through the glucose transporters. J Clin investigation. 1997;100:2842–8. Niki E. Interaction of ascorbate and alpha-tocopherol. Ann N Y Acad Sci. 1987;498:186–99. Guo Q, Packer L. Ascorbate-dependent recycling of the vitamin E homologue Trolox by dihydrolipoate and glutathione in murine skin homogenates. Free Radic Biol Med. 2000;29:368–74. Zhang SM, Hernán MA, Chen H, Spiegelman D, Willett WC, Ascherio A. Intakes of vitamins E and C, carotenoids, vitamin supplements, and PD risk. Neurology. 2002;59:1161–9. Etminan M, Gill SS, Samii A. Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson’s disease: a meta-analysis. Lancet Neurol. 2005;4:362–5. Olanow CW. Dietary vitamin E and Parkinson’s disease: something to chew on. Lancet Neurol. 2003;2:74. Ebrahimi A, Kamyab A, Hosseini S, Ebrahimi S, Ashkani-Esfahani S. Involvement of coenzyme Q10 in various neurodegenerative and psychiatric diseases. Biochem Res Int. 2023;2023:5510874. Zhang Y, Liu J, Chen XQ, Oliver Chen CY. Ubiquinol is superior to ubiquinone to enhance Coenzyme Q10 status in older men. Food Funct. 2018;9:5653–9. Kaufmann P, Thompson JL, Levy G, Buchsbaum R, Shefner J, Krivickas LS, et al. Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann Neurol. 2009;66:235–44. Beal MF, Oakes D, Shoulson I, Henchcliffe C, Galpern WR, Haas R, et al. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurol. 2014;71:543–52. McGarry A, McDermott M, Kieburtz K, de Blieck EA, Beal F, Marder K, et al. A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease. Neurology. 2017;88:152–9. Mantle D, Heaton RA, Hargreaves IP. Coenzyme Q10, Ageing and the Nervous System: An Overview. Antioxidants. 2021;11:2. Halder S, Nasrin F, Chandra Shill M, Shuma ML, Sultan MZ, Reza MS. Improved biopharmaceutical performance of coenzyme Q10 through solid lipid nanoparticles for enhanced brain delivery. Scientifica. 2025;2025:9034181. Dodson M, Castro-Portuguez R, Zhang DD. NRF2 plays a critical role in mitigating lipid peroxidation and ferroptosis. Redox Biol. 2019;23:101107. Anandhan A, Dodson M, Schmidlin CJ, Liu P, Zhang DD. Breakdown of an ironclad defense system: the critical role of NRF2 in mediating ferroptosis. Cell Chem Biol. 2020;27:436–47. Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367:1098–107. Schepici G, Bramanti P, Mazzon E. Efficacy of sulforaphane in neurodegenerative diseases. Int J Mol Sci. 2020;21:8637. Wu N, Luo Z, Deng R, Zhang Z, Zhang J, Liu S, et al. Sulforaphane: an emerging star in neuroprotection and neurological disease prevention. Biochemical pharmacology. 2025;233:116797. Prosperini L, Pontecorvo S. Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerations. Therapeutics Clin risk Manag. 2016;12:339–50. Lee A. Omaveloxolone: first approval. Drugs. 2023;83:725–9. Reetz K, Lischewski SA, Dogan I, Didszun C, Pishnamaz M, Konrad K, et al. Friedreich’s ataxia-a rare multisystem disease. Lancet Neurol. 2025;24:614–24. Lynch DR, Chin MP, Delatycki MB, Subramony SH, Corti M, Hoyle JC, et al. Safety and efficacy of omaveloxolone in friedreich ataxia (MOXIe Study). Ann Neurol. 2021;89:212–25. Pilotto F, Chellapandi DM, Puccio H. Omaveloxolone: a groundbreaking milestone as the first FDA-approved drug for Friedreich ataxia. Trends Mol Med. 2024;30:117–25. Soriano-Castell D, Liang Z, Maher P, Currais A. Profiling the chemical nature of anti-oxytotic/ferroptotic compounds with phenotypic screening. Free Radic Biol Med. 2021;177:313–25. Lee KH, Cha M, Lee BH. Neuroprotective effect of antioxidants in the brain. Int J Mol Sci. 2020;21:7152. Quinti L, Dayalan Naidu S, Träger U, Chen X, Kegel-Gleason K, Llères D, et al. KEAP1-modifying small molecule reveals muted NRF2 signaling responses in neural stem cells from Huntington’s disease patients. Proc Natl Acad Sci USA. 2017;114:E4676–e4685. Flanagan E, Lamport D, Brennan L, Burnet P, Calabrese V, Cunnane SC, et al. Nutrition and the ageing brain: moving towards clinical applications. Ageing Res Rev. 2020;62:101079. Hayes JD, Dinkova-Kostova AT. The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. Trends biochemical Sci. 2014;39:199–218. Calabrese V, Cornelius C, Mancuso C, Barone E, Calafato S, Bates T, et al. Vitagenes, dietary antioxidants and neuroprotection in neurodegenerative diseases. Front Biosci. 2009;14:376–97. Andreo-López MC, Contreras-Bolívar V, Muñoz-Torres M, García-Fontana B, García-Fontana C. Influence of the mediterranean diet on healthy aging. Int J Mol Sci. 2023;24:4491. Zhang H, Davies KJA, Forman HJ. Oxidative stress response and Nrf2 signaling in aging. Free Radic Biol Med. 2015;88:314–36. Satoh H, Moriguchi T, Takai J, Ebina M, Yamamoto M. Nrf2 prevents initiation but accelerates progression through the Kras signaling pathway during lung carcinogenesis. Cancer Res. 2013;73:4158–68. Wiel C, Le Gal K, Ibrahim MX, Jahangir CA, Kashif M, Yao H, et al. BACH1 stabilization by antioxidants stimulates lung cancer metastasis. Cell. 2019;178:330–.345.e322. Tao S, Rojo de la Vega M, Chapman E, Ooi A, Zhang DD. The effects of NRF2 modulation on the initiation and progression of chemically and genetically induced lung cancer. Mol carcinogenesis. 2018;57:182–92. Sun S, Shen J, Jiang J, Wang F, Min J. Targeting ferroptosis opens new avenues for the development of novel therapeutics. Signal Transduct Target Ther. 2023;8:372. Lofts A, Abu-Hijleh F, Rigg N, Mishra RK, Hoare T. Using the intranasal route to administer drugs to treat neurological and psychiatric illnesses: rationale, successes, and future needs. CNS drugs. 2022;36:739–70.